is semaglutide a compound drug Troubling Findings in Study of GLP-1 Compounders The market for compounded GLP-1

The receptor belongs to the G-protein coupled 7 transmembrane domain family and has 40% homology to the secretin receptor

The peptide binds to GIP and GLP-1 receptors continuously once plasma concentrations reach therapeutic range, which occurs 1224 hours after the first injection and remains elevated for the entire 7-day dosing interval

The 12mg dose produced the greatest average weight loss in the trial, but it was also associated with higher rates of gastrointestinal side effects

Investigational GLP-1 patches use specialised technologies such as microneedles to deliver large peptide molecules across the skin barrier